about
Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) studyFactors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010.Home visits during pregnancy enhance male partner HIV counselling and testing in Kenya: a randomized clinical trialThe effect of HIV counselling and testing on HIV acquisition in sub-Saharan Africa: a systematic reviewAdherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence.Evaluation of pigtail macaques as a model for the effects of copper intrauterine devices on HIV infection.Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study.Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques.Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.Blocking CXCL9 Decreases HIV-1 Replication and Enhances the Activity of Prophylactic Antiretrovirals in Human Cervical Tissues.From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City.Role of medication therapy management in preexposure prophylaxis therapy for HIV prevention.Women and ARV-based prevention: opportunities and challenges.Methods for measuring, enhancing, and accounting for medication adherence in clinical trials.
P2860
Q27300707-76BB3CA5-7931-4285-AA36-9AF03A2D22D1Q27318158-6083CD5C-5927-4B57-B73B-78D5C6A4A447Q28649558-D195157C-6867-47B9-9F7F-91B22C789FC6Q30248456-4DA82181-970C-4B4B-B48A-4D7D2ABBC09AQ33765789-B45D265D-7611-4996-AAF7-342037087CB4Q33818024-7C4799A7-451C-427D-B020-9BE8D7386ABEQ34180615-1DBE2D65-9246-4339-8F21-5F063F7B37CFQ34180736-92182D05-D878-454E-BD88-F5D12AE4B151Q34421999-7CF116AE-F351-46C9-8F81-C6E7B62930B5Q35659488-3D61B344-E0DE-472C-825E-8E68ED7DE937Q36678079-BD000A49-CD2A-4EE2-9936-7015DE838FAFQ36760768-F31A3480-5061-4EF5-9D0F-06D0444F07E8Q41602868-9C91460B-AEE9-45A3-8455-2410E38C4B62Q46553256-F8B02761-62E0-4A95-A68D-73FD526E1D88Q46630774-F8CF51FB-0DC9-47D8-9605-E28E484D834F
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Oral antiretroviral chemoprophylaxis: current status.
@ast
Oral antiretroviral chemoprophylaxis: current status.
@en
type
label
Oral antiretroviral chemoprophylaxis: current status.
@ast
Oral antiretroviral chemoprophylaxis: current status.
@en
prefLabel
Oral antiretroviral chemoprophylaxis: current status.
@ast
Oral antiretroviral chemoprophylaxis: current status.
@en
P2860
P1476
Oral antiretroviral chemoprophylaxis: current status.
@en
P2093
Jared Baeten
P2860
P304
P356
10.1097/COH.0B013E3283582D30
P50
P577
2012-11-01T00:00:00Z